NUTRA PHARMA

Nutra Pharma Corp., a biopharmaceutical company, engages in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiary, ReceptoPharm, Inc., develops RPI-78M for the treatment of neurological diseases, multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, and myasthenia gravis; and RPI-MN for the treatment of the viral diseases, HIV/AIDS, and hepatitis-C. In addition, the company, through its other subsidiary, Designer Diagnostics, Inc., engages in the sale of diagnostic test kits that are used for the identification of infectious human diseases, such as tuberculosis and mycobacterium avium-intracellulare.